RxDoctor Payments Data

Michelle Lyon, MD

Neurology · Aiken, SCNPI 1164476479

Payments from drug & device makers

$1,055in general payments, 2019–2025

Across 37 payments — averaging $28.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mindray DS USA, Inc.$313
  • AbbVie$191
  • Livanova USA, Inc.$108
  • Lundbeck LLC$97
  • Pfizer$57
  • Biohaven Pharmaceutical Holding Company Ltd.$39
  • plus $251 from 12 others

What the payments were for

  • Food & beverage$1,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,055 in reported general payments places this provider in the 50th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$193,605
Medicare patients
379
Services billed
11,443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe36$35,918
QuliptaAtogepant19$24,817
UbrelvyUbrogepant26$23,485
Ajovy SyringeFremanezumab-Vfrm12$8,561
Memantine Hcl142$5,089
Duloxetine Hcl68$3,091
Donepezil Hcl168$3,084
Carbidopa-LevodopaCarbidopa/Levodopa99$2,880
Topiramate ErTopiramate11$2,775
Gabapentin159$2,757
Propranolol Hcl ErPropranolol Hcl60$2,167
Ropinirole Hcl58$1,682
Pregabalin76$1,342
Sumatriptan Succinate75$984
Levetiracetam23$655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$191$48,30145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 270 neurology providers in South Carolina.

Other neurology in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →